anti-programmed cell death-1 antibody conjugated delta opioid receptor-targeted immunotherapy agents (Celgene/H Lee Moffitt Cancer Center & Research Institute/University of South Florida/West Virginia University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-programmed cell death-1 antibody conjugated delta opioid receptor-targeted immunotherapy agents (Celgene/H Lee Moffitt Cancer Center & Research Institute/University of South Florida/West Virginia University)
Drug Alias NameDORL 12-PD-1 (Celgene/H Lee Moffitt Cancer Center & Research Institute/University of South Florida/West Virginia University)DORL9-PD-1 (Celgene/H Lee Moffitt Cancer Center & Research Institute/University of South Florida/West Virginia University)DORL6-PD-1 (Celgene/H Lee Moffitt Cancer Center & Research Institute/University of South Florida/West Virginia University)DORL6-PD-1DORL9-PD-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of Actionδ-opioid receptor modulatorsImmunomodulators
Targetsδ-opioid receptor
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of South FloridaH Lee Moffitt Cancer Center & Research InstituteCelgene Corp +[4] 
Active IndicationsN/A
Inactive IndicationsLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A